Treatment options: the latest evidence with galantamine (Reminyl). (Q34989474)

5 August 2017

1 reference

title

Treatment options: the latest evidence with galantamine (Reminyl). (English)

1 reference

5 August 2017

1

Timo Erkinjuntti

1 reference

5 August 2017

1 November 2002

1 reference

Journal of the Neurological Sciences

5 August 2017

1 reference

5 August 2017

203-204

1 reference

5 August 2017

125-130

1 reference

Prevalence and outcomes of vascular cognitive impairment

5 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900267-8

Worldwide prevalence and incidence of dementia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900267-8

Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900267-8

Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer-type dementia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900267-8

Changes in nicotinic acetylcholine receptor subunit mRNAs and nicotinic binding in spontaneously hypertensive stroke prone rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900267-8

An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900267-8

Use of donepezil for vascular dementia: preliminary clinical experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900267-8

Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900267-8

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900267-8

A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900267-8

Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900267-8

Sensitivity and specificity of newly proposed clinical criteria for possible vascular dementia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900267-8

Reliability of NINDS-AIREN clinical criteria for the diagnosis of vascular dementia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900267-8

Vascular Dementia Is Underdiagnosed

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900267-8

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900267-8

A new rating scale for Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900267-8

Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900267-8

The Neuropsychiatric Inventory: assessing psychopathology in dementia patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900267-8

Current status and new developments with galantamine in the treatment of Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900267-8

Status of risk factors for vascular dementia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900267-8

The relationship between blood pressure and dementia: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900267-8

Randomized clinical trial of daily aspirin therapy in multi-infarct dementia. A pilot study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900267-8

Practice parameter: Management of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900267-8

Propentofylline in the treatment of Alzheimer's disease and vascular dementia: a review of phase III trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900267-8

Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2802%2900267-8

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0022-510X(02)00267-8

1 reference

5 August 2017

1 reference

PubMed ID

12417370